Owlet Announces FDA-Clearance of the First Prescription Pulse Oximetry Sock for Infants
LEHI, Utah--(BUSINESS WIRE)--Owlet (NYSE: OWLT, “the Company”), the pioneer of smart baby monitoring, announces clearance from the U.S. Food and Drug Administration (“FDA”) of BabySat™, the first medical pulse-oximetry device featuring its advanced, wire-free sock design. Owlet is a leader in infant health data, having monitored more than 1 million babies, and with BabySat, combines its consumer-first expertise with hospital-grade monitoring accuracy. “Our mission is to provide caregivers with ...
